Johnson & Johnson stock stays supported by earnings scale

Johnson & Johnson stock keeps a large earnings base after fiscal 2025 revenue reached $88.8 billion and adjusted operational sales rose 4.2% on 16 July 2026. The latest quarterly and annual figures also show $14.1 billion in net earnings for fiscal 2025 and $23.9 billion in operating cash flow.

Johnson & Johnson (ISIN US4781601046) stock stays anchored by scale: fiscal 2025 revenue reached $88.8 billion, adjusted operational sales rose 4.2%, and net earnings were $14.1 billion, according to the companys fiscal 2025 results. The same report showed operating cash flow of $23.9 billion and a 2025 dividend payout of $5.1 billion, all dated 16 July 2026.

Revenue at $88.8 billion

The top line of $88.8 billion in fiscal 2025 gives Johnson & Johnson a wide base even without a fresh market quote in hand. The companys adjusted operational sales growth of 4.2% shows that volume and mix still moved in the right direction in 2025, while diluted EPS from continuing operations was $5.79 and adjusted diluted EPS was $10.65.

That spread matters for investors because it separates reported earnings from the companys core operating run rate. It also gives a cleaner view of how the portfolio performed across the year ending 16 July 2026, when the company reported these figures.

Cash flow at $23.9 billion

Operating cash flow of $23.9 billion in fiscal 2025 remains one of the more useful numbers in the set because it captures the companys ability to fund research, dividends, and debt service. Johnson & Johnson also reported $5.1 billion in dividends paid during 2025, which underlines the scale of the capital return commitment.

Net earnings of $14.1 billion in fiscal 2025 were lower than the adjusted profit measure, but the combination of cash generation and earnings still points to a large financial cushion. For a company of this size, the cash figure is often the cleaner reference point when the market is waiting for the next catalyst.

Adjusted EPS at $10.65

The most market-relevant comparison in the report is the gap between diluted EPS of $5.79 and adjusted diluted EPS of $10.65 for fiscal 2025. That difference shows how much one-time items and reporting structure can change the headline profit picture.

It also explains why the earnings release remains the key source for valuation work even on a day without a live quote in the search results. A large healthcare group with $88.8 billion in annual revenue and $23.9 billion in operating cash flow still gives the stock a measurable fundamental floor.

Product line and scale

Johnson & Johnsons pharmaceutical and medtech franchises remain the main commercial engine behind those numbers, with the company using the breadth of its product mix to support annual cash generation. The fiscal 2025 release shows that the portfolio can still turn revenue into cash at a scale that matters for both dividends and reinvestment.

For readers tracking the name over time, the core point is simple: the business is still large enough that even modest percentage changes can translate into multibillion-dollar swings in sales, profit, and cash flow.

Market level and venue

Johnson & Johnson is listed on the NYSE, and the article therefore uses the companys U.S. equity context. The body metrics above are the most recent dated figures available in this call and provide the current reference point for the stock.

On that basis, the stock story today is less about a single trading session and more about the durability of a business that generated $88.8 billion in revenue, $14.1 billion in net earnings, and $23.9 billion in operating cash flow in fiscal 2025.

Annual figures that matter

Johnson & Johnsons fiscal 2025 report is still the cleanest source for the stock narrative because it combines revenue, earnings, and cash flow in one dated package. The annual numbers also avoid the noise that can distort a single-session price move.

Stock closing view

The companys NYSE listing and fiscal 2025 operating base remain the key reference points here, with $88.8 billion in revenue, $23.9 billion in operating cash flow, and $10.65 in adjusted diluted EPS all dated to the 16 July 2026 report. Those figures are enough to frame the stock without forcing an unverified live quote into the story.

Johnson & Johnson fact box

• Company: Johnson & Johnson
• ISIN: US4781601046
• Ticker: NYSE: JNJ
• Trading venue: NYSE
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: Dow Jones Industrial Average